ストックスクリーナーアプリを入手
128.07
0.70%
0.89
アフターアワーズ：
128.00
-0.07
-0.05%
前日終値:
$127.18
開ける：
$127.09
24時間の取引高:
6.76M
Relative Volume:
0.98
時価総額：
$58.65B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
19.84
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
+3.78%
1か月 パフォーマンス:
+4.28%
6か月 パフォーマンス:
+20.64%
1年 パフォーマンス:
+45.95%
1日の値動き範囲:
$125.86
$128.10
1週間の範囲:
$122.50
$128.10
52週間の値動き範囲:
$87.77
$128.10
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
128.07 | 157.79B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,049.60 | 921.91B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.51 | 481.86B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
342.40 | 185.23B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
232.91 | 413.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
95.05 | 239.34B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences' GC Will Leave Co. Next Month - Law360
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment - Benzinga
Without Explanation, Gilead Sciences Parts Ways With GC It Wooed Aboard in 2022 - Law.com
Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial - Reuters
Gilead Sciences (GILD) Announces Executive Leadership Change - GuruFocus
Gilead at Jefferies London: Strategic Growth and Innovation - Investing.com India
Gilead Sciences (GILD): Assessing Valuation After Strong Shareholder Returns and Product Pipeline Developments - simplywall.st
Gilead Sciences announces departure of executive vice president and general counsel - Investing.com
Gilead Sciences Announces Executive Vice President Departure - TipRanks
WBI Investments LLC Has $1.66 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead says Deborah Telman to step down as evp at Gilead SciencesSEC filing - MarketScreener
Gilead Sciences announces executive departure in December - StreetInsider
Vanguard Group Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Westover Capital Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead reports Trodelvy breast cancer trial missed primary survival endpoint - PMLiVE
'Gilead wants us to rebuild': Why Galapagos isn't allowed to go extinct after turbulent year - Fierce Biotech
Merck HIV pill matches Gilead’s Biktarvy in trial (MRK:NYSE) - Seeking Alpha
Invenio Wealth Partners LLC Buys Shares of 3,333 Gilead Sciences, Inc. $GILD - MarketBeat
SG Americas Securities LLC Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: A Study in Corporate Contrasts - Ad-hoc-news.de
Why Gilead Sciences Inc. (GIS) stock is a strong analyst pickJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Gilead Sciences Insider Sold Shares Worth $3,524,173, According to a Recent SEC Filing - MarketScreener
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead joins partners for delivery of first shipments of breakthrough twice-yearly lenacapavir for HIV prevention to sub-Saharan Africa - European AIDS Treatment Group
Gilead Sciences’ (GILD) chief commercial officer sells $3.5m in stock - Investing.com UK
Raiffeisen Bank International AG Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nomura Asset Management Co. Ltd. Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
First doses of HIV prevention drug lenacapavir delivered to Zambia, Eswatini - Reuters
Gilead Sciences, Inc. $GILD is LSV Asset Management's 9th Largest Position - MarketBeat
Thoroughbred Financial Services LLC Has $1.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Citizens Financial Group Inc. RI - MarketBeat
Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa - GuruFocus
Gilead ships first lenacapavir doses to sub-Saharan Africa - StreetInsider
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa - Business Wire
Cetera Investment Advisers Purchases 21,966 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3... - Medical Dialogues
Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market - BioSpace
Is It Too Late to Reassess Gilead After Recent Drug Trial Success? - simplywall.st
Will Gilead Sciences Inc. stock deliver long term returnsJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Gilead Sciences's Options: A Look at What the Big Money is Thinking - Benzinga
Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Raised by Westpac Banking Corp - MarketBeat
Letko Brosseau & Associates Inc. Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Persistent Asset Partners Ltd Invests $767,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Foundations Investment Advisors LLC Buys 17,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Creative Planning Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Where speed meets science in Gilead’s approach to drug development - Endpoints News
Crossmark Global Holdings Inc. Sells 39,563 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Cornerstone Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Avantax Advisory Services Inc. - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
135,193 |
| Mercier Johanna | Chief Commercial Officer |
Nov 17 '25 |
Sale |
125.86 |
28,000 |
3,524,173 |
107,193 |
2.17%
大文字化:
|
ボリューム (24 時間):